EyePoint Stock: Retaining My 'Risky Buy' Call - Pivotal Data Due Early 2026
Source: SeekingAlpha
2025-06-12 11:03:51 ET
Investment Overview
Back in January this year, I covered EyePoint Pharmaceuticals, Inc. ( EYPT ) in a note for Seeking Alpha , calling its stock a "risky buy" ahead of a key readout for its lead and only clinical stage drug candidate Duravyu - vorolanib intravitreal insert - in patients suffering from diabetic macular edema - a serious eye condition that can result in vision loss....
Read the full article on Seeking Alpha
For further details see:
EyePoint Stock: Retaining My 'Risky Buy' Call - Pivotal Data Due Early 2026
Opthea Limited
NASDAQ: OPT
OPT Trading
-2.05% G/L:
$3.41 Last:
3,025 Volume:
$3.48 Open:
OPT Latest News
OPT Stock Data
$583,100,698
167,235,331
N/A
12
537820%
Biotechnology & Life Sciences
Healthcare
AU
South Yarra
